<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314181</url>
  </required_header>
  <id_info>
    <org_study_id>M15-654</org_study_id>
    <secondary_id>2017-002099-26</secondary_id>
    <nct_id>NCT03314181</nct_id>
  </id_info>
  <brief_title>A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib
      combination therapy to evaluate safety, tolerability, and efficacy of these combinations in
      participants with relapsed or refractory multiple myeloma. The study will consist of 3
      distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R)
      multiple myeloma who will receive venetoclax in combination with daratumumab and
      dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will
      receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd);
      Part 3 includes participants with t(11;14) positive R/R multiple myeloma who will receive
      venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab,
      bortezomib, and dexamethasone (DVd).

      Part 1 and Part 2 are non-randomized and will be initiated with a dose-escalation phase in
      which increasing doses of venetoclax will be given with fixed doses of daratumumab and
      dexamethasone (Part 1a) or with fixed doses of daratumumab, bortezomib, and dexamethasone
      (Part 2a). Each dose escalation phase will be followed by a single-arm, open-label expansion
      phase. Part 3 will include a randomized, open-label expansion phase with participants
      receiving venetoclax in combination with daratumumab and dexamethasone (VenDd) or
      daratumumab, bortezomib, and dexamethasone (DVd).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">June 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 3.5 years after the last participant is enrolled</time_frame>
    <description>ORR is defined as the percentage of participants with documented partial response (PR) or better based on International Myeloma Working Group (IMWG) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) or Better Rate</measure>
    <time_frame>Up to approximately 3.5 years after the last participant is enrolled</time_frame>
    <description>CR or better response is defined as the percentage of participants with documented response of CR or better (stringent complete response [sCR] or CR) based on IMWG criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Very Good Partial Response or Better Response Rate (VGPR)</measure>
    <time_frame>Up to approximately 3.5 years after the last participant is enrolled</time_frame>
    <description>VGPR or better response rate is defined as the proportion of participants with documented VGPR or better (sCR, CR. or VGPR) based on IMWG criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to approximately 3.5 years after the last participant is enrolled</time_frame>
    <description>TTP is defined as the number of days from the date of treatment start (for subjects enrolled prior to randomization start) or randomization (for randomized subjects) to the date of first documented PD or death due to MM, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 3.5 years after the last participant is enrolled</time_frame>
    <description>DOR is defined as the number of days from the participant's date of first documented response (PR or better) to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 3.5 years after the last participant is enrolled</time_frame>
    <description>PFS is defined as the number of days from the date of treatment start (for subjects enrolled prior to randomization start) or randomization (for randomized subjects) to the date of the first documented PD or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Venetoclax</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 of Venetoclax</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) over the dose interval (AUC0-24) of venetoclax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Venetoclax</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Time to Cmax (Tmax) of Venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>Up to 12 months after confirmation of Complete Response (CR) or Stringent Complete Response (sCR)</time_frame>
    <description>MRD negativity in bone marrow aspirates is defined at 10^-5 threshold as assessed by next generation sequencing (NGS) in participants at the time of suspected CR/sCR, and at 6 and 12 months post confirmation of CR/sCR for participants who maintained this response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to approximately 3.5 years after the last participant is enrolled</time_frame>
    <description>TTR is defined as the number of days from the date of treatment start (for subjects enrolled prior to randomization start) or randomization (for randomized subjects) to the date of first documented response of PR or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 3.5 years after the last participant is enrolled</time_frame>
    <description>OS is defined as the number of days from the date of treatment start (for subjects enrolled prior to randomization start) or randomization (for randomized subjects) to the date of death.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A, Part 1a: VenDd Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (1800 mg subcutaneous injection (preferred) or 16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, Part 1b: VenDd Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at various doses administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F: VenDd Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G: VenDd Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H: DVd Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8: Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg on Cycles 1 - 3: Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) on Cycles 4-8: Days 1,2,4,5,8,9,11 and 12; 20 mg monthly for Cycles 9+: Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Administered intravenously (IV) or as a tablet taken orally</description>
    <arm_group_label>Arm A, Part 1a: VenDd Dose Escalation</arm_group_label>
    <arm_group_label>Arm B, Part 1b: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
    <arm_group_label>Arm F: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm G: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm H: DVd Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Administered by subcutaneous injection (preferred) or intravenously (IV)</description>
    <arm_group_label>Arm A, Part 1a: VenDd Dose Escalation</arm_group_label>
    <arm_group_label>Arm B, Part 1b: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
    <arm_group_label>Arm F: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm G: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm H: DVd Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Tablet taken orally</description>
    <arm_group_label>Arm A, Part 1a: VenDd Dose Escalation</arm_group_label>
    <arm_group_label>Arm B, Part 1b: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
    <arm_group_label>Arm F: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm G: VenDd Dose Expansion</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Administered by subcutaneous injection (preferred) or intravenously (IV)</description>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
    <arm_group_label>Arm H: DVd Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;= 2.

          -  Participant has relapsed or refractory multiple myeloma with documented evidence of
             progression that occurred during or after the participant's last treatment regimen
             based on investigator's determination of International Myeloma Working Group (IMWG)
             criteria.

          -  Measurable disease confirmed by central lab at Screening, defined by at least 1 of the
             following: Serum M-protein &gt;= 1.0 g/dL (&gt;= 10 g/L), OR Urine M-protein &gt;= 200 mg/24
             hours, OR Serum free light chain (FLC) &gt;= 10 mg/dL, provided serum FLC ratio is
             abnormal in participants who do not have measurable disease by Serum Protein
             Electrophoresis (SPEP) or Urine Protein Electrophoresis (UPEP) criteria.

          -  Participant has received previous multiple myeloma treatment as defined in the
             protocol.

          -  Bone marrow aspirate samples have been collected.

          -  To qualify for Part 1 and 3, the participant must be t(11;14) positive as determined
             by an analytically validated Fluorescent In Situ Hybridization (FISH) assay per
             central laboratory testing.

          -  Participants must have adequate hematologic, renal and hepatic function.

        Exclusion Criteria:

          -  Previous treatment with venetoclax or other B-Cell Lymphoma 2 (BCL-2) inhibitor OR
             previous treatment with daratumumab or other anti-CD38 therapy.

          -  For participants in Part 2 and 3:

               1. Participant is refractory to any proteasome inhibitor, defined as progression on
                  or within 60 days of the last dose of a proteasome inhibitor-containing regimen.

               2. Participant has had prior treatment with proteasome inhibitor within 60 days
                  prior to first dose of study drug.

          -  Treatment with anti-myeloma chemotherapy, radiotherapy, biological, immunotherapy or
             an investigational therapy, including targeted small molecule agents within 2 weeks or
             5 half-lives (whichever is longer and/or applicable) before first dose.

          -  Treatment with anti-myeloma monoclonal antibodies within 6 weeks prior first dose.

          -  Recent corticosteroid therapy at a cumulative dose equivalent to &gt;= 140 mg of
             prednisone or a single dose equivalent to &gt;= 40 mg of dexamethasone within 2 weeks
             prior the first dose of study drug.

          -  Known meningeal involvement of multiple myeloma.

          -  Significant history of medical conditions as listed in the protocol.

          -  History of other active malignancies including myelodysplatic syndromes (MDS) within
             the past 3 years with the exceptions of:

               1. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the
                  skin.

               2. Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific
                  Antigen (PSA) levels off treatment

               3. Previous malignancy with no evidence of disease confirmed and surgically resected
                  (or treated with other modalities) with curative intent and unlikely to impact
                  survival during the duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center /ID# 167331</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center /ID# 169614</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital /ID# 165427</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 165429</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center /ID# 210904</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 166886</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center /ID# 169615</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine/NYP /ID# 167605</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-4872</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atrium Health Carolinas Medical Center /ID# 164948</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center /ID# 165104</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science Universi /ID# 166822</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington /ID# 164884</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, Darlinghurst /ID# 165431</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George Hospital /ID# 171063</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 171060</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern Health /ID# 165850</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincents Hosp Melbourne /ID# 165853</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Ctr /ID# 164742</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary /ID# 167822</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute /ID# 203114</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill Univ HC /ID# 167824</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet /ID# 164420</name>
      <address>
        <city>Copenhagen Ø</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital /ID# 164509</name>
      <address>
        <city>Aarhus N</city>
        <state>Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Odense Universitets Hospital /ID# 164417</name>
      <address>
        <city>Odense C</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sygehus Lillebaelt - Vejle Syg /ID# 164418</name>
      <address>
        <city>Vejle</city>
        <state>Syddanmark</state>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Bretonneau - CHU Tours /ID# 164795</name>
      <address>
        <city>Tours CEDEX 9</city>
        <state>Indre-et-Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu /ID# 164767</name>
      <address>
        <city>Nantes CEDEX 1</city>
        <state>Pays-de-la-Loire</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers /ID# 164806</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute Gustave Roussy /ID# 164807</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne /ID# 166037</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg /ID# 166036</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>t(11,14) positive relapsed/refractory (R/R) multiple myeloma</keyword>
  <keyword>Non-refractory Relapsed Multiple Myeloma</keyword>
  <keyword>Non-refractory Refractory Multiple Myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

